logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Friday, May 9, 2025 · 810,994,556 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Revlimid News Monitoring

  • Published on May 8, 2025

    Newer Trials Explore High-Risk Treatment and MRD in Multiple Myeloma

    Kathleen A. Dorritie, MD Hematologist/Medical Oncologist UPMC Hillman Cancer Center Pittsburgh, PA In this Community Case Forum event from Pittsburgh, Pennsylvania led by Kathleen A. Dorritie, MD, a hematologist/medical oncologist at UPMC Hillman …

    Source: Targeted Oncology - Pending
  • Published on May 8, 2025

    Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2025 Earnings Call Transcript

    Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2025 Earnings Call Transcript May 7, 2025 Teva Pharmaceutical Industries Limited beats earnings expectations. Reported EPS is $0.52, expectations were $0.47. Operator: Hello, and welcome to the Q1 2025 …

    Source: Insider Monkey - Neutral
  • Published on May 7, 2025

    Multiple Myeloma Treatment: The Price of Success

    Editor's note: This is expanded version of an article that was posted as part of coverage of the 2025AMCP Annual Meeting. The treatment of multiple myeloma is often described as complicated or complex. The description is apt and reflects the fact that …

    Source: Managed Healthcare Executive - Neutral
  • Published on May 8, 2025

    The Price of Remission

    ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. The pain jolted me awake. It was barely dawn, a misty February morning in 2023. My side felt as if I’d been stabbed. …

    Source: ProPublica - Left-wing
  • Published on May 7, 2025

    RX Road Map: Daratumumab and Hyaluronidase-fihj

    Who Is This Drug Approved For? The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with multiple myeloma and are eligible for autologous stem cell transplant. In this patient population, …

    Source: Oncology Nursing News - Pending
  • Published on Jan 2, 2025

    Regulatory tracker: EMA restricts use of Valneva's Ixchiq in older adults, begins safety review

    Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly for …

    Source: Fierce Pharma - Neutral
  • Published on May 8, 2025

    Judge deals blow to compounding pharmacies

    Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’ve got more news today about Vinay Prasad — let’s get into it. Vinay Prasad makes his debut at FDA One day after he …

    Source: STAT - Massachusetts - Neutral
  • Published on May 8, 2025

    Dr Reddy’s Labs Q4 Preview: PAT may jump up to 12% YoY, revenue to rise up to 18% on generics business dose

    Pharma major Dr Reddy’s Laboratories will announce its Q4FY25 earnings on Friday where the company is expected to report a net profit growth of 1.3% to 12% on a year-on-year basis, according to estimates by four brokerages. The bottom line is likely to be …

    Source: The Economic Times - Pending
  • Published on May 8, 2025

    Dr Kahl on the Outcomes of Bortezomib Plus BR in MCL

    “The study showed that adding bortezomib to the bendamustine/rituximab induction did not improve the 2-year progression-free survival, [which] came in right around 75% to 80% in both arms, and [the bortezomib regimen] didn’t improve the complete …

    Source: OncLive - Pending
  • Published on May 8, 2025

    Teva on course for 2027 targets

    Nearly a decade ago, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) found itself mired in a liquidity crisis that placed in doubt its ability to repay the huge debt it had taken to finance the $40 billion acquisition of Activis from Allergan. …

    Source: Globes - Pending
  • Published on May 8, 2025

    Teva’s quiet layoff announcement reveals bold restructuring plan

    Teva Pharmaceuticals offered a long-awaited explanation for the sharp 10% jump in its share price last week. But the gains come at a steep human cost. The Israeli drugmaker reassured investors with a revised, more optimistic profit forecast—after a …

    Source: CTech - Neutral
  • Published on May 8, 2025

    Hundreds of Israeli workers could be affected by Teva layoffs

    Teva Pharmaceutical Industries offered an explanation for the impressive 10% surge in its stock over the past week—but the news came with a steep cost. The Israeli pharmaceutical giant reassured investors with a pledge to improve profitability after a …

    Source: Ynet - Indeterminate
  • Published on May 5, 2025

    "Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

    The PERSEUS (NCT03710603) and CEPHEUS (NCT03652064) trials both demonstrated improved depth and duration of responses and progression-free survival (PFS) with a quadruplet regimen of daratumumab plus bortezomib (Velcade), lenalidomide (Revlimid), and …

    Source: The American Journal of Managed Care - Neutral
  • «
  • 1
  • »

03 days 20:41:27

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 810,994,556 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 04/18/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement